Share price · VKTX
Loading chart…
Prices are end-of-day (EOD), delayed by 24 hours · Adjusted for stock splits · Data via Databento
Unusual price moves
Days when VKTX's shares moved far more than they usually do, with what was announced that day or the session before. An announcement on the same day does not show that it caused the move. How the days are picked
- 24 Sep 2026-11.8%
- 22 Sep 2026+35.7%
- 23 Jul 2026-5.1%
- 7 Jul 2026+8.8%
Nothing announced by VKTX that day or the session before.
- 24 Jun 2026+8.8%
- 23 Jun 2026+7.5%
Nothing announced by VKTX that day or the session before.
- 30 Mar 2026-8.0%
Nothing announced by VKTX that day or the session before.
- 23 Feb 2026+11.1%
Nothing announced by VKTX that day or the session before.
- 12 Feb 2026+6.8%
- 5 Feb 2026-11.1%
Share of unusual movement by asset
For each asset, the share of VKTX's own-move activity since 2 Jul 2024 that fell on the session of one of the asset's own announcements or the session after it. Large moves count for much more than small ones. A session shared by several assets is split between them. A share is shown once an asset has at least 8 event days; below that, its events are listed instead.
Assets
(3 total)
Upcoming events
(4 total)
Estimated primary-completion dates from ClinicalTrials.gov and expected earnings reports. These are registry estimates, never confirmed readout dates; they can move as trials progress.
Add these trial readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.
2027 (2)
Regulatory and conference events
(2)
Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.
Recent
Financial reports
Quarterly & interim (16)
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2026-Q3 | $0 | $167M | $678M+ $282M short-term inv. | $183M-$138M operating cash flow | report ↗ |
View 15 more
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2026-Q2 | $0 | $116M | $126M+ $376M short-term inv. | $128M-$125M operating cash flow | report ↗ |
| 2026-Q1 | $0 | $150M | $118M+ $485M short-term inv. | $158M-$114M operating cash flow | report ↗ |
| 2025-Q3 | $0 | $90M | $100M+ $614M short-term inv. | $91M-$94M operating cash flow | report ↗ |
| 2025-Q2 | $0 | $60M | $34M+ $774M short-term inv. | $66M-$47M operating cash flow | report ↗ |
| 2025-Q1 | $0 | $41M | $38M+ $814M short-term inv. | $46M-$52M operating cash flow | report ↗ |
| 2024-Q3 | $0 | $23M | $50M+ $880M short-term inv. | $25M-$22M operating cash flow | report ↗ |
| 2024-Q2 | $0 | $24M | $44M+ $898M short-term inv. | $22M-$29M operating cash flow | report ↗ |
| 2024-Q1 | $0 | $24M | $196M+ $767M short-term inv. | $27M-$6.1M operating cash flow | report ↗ |
| 2023-Q3 | $0 | $18M | $37M+ $339M short-term inv. | $23M-$20M operating cash flow | report ↗ |
| 2023-Q2 | $0 | $14M | $70M+ $323M short-term inv. | $19M-$11M operating cash flow | report ↗ |
| 2023-Q1 | $0 | $11M | $18M+ $117M short-term inv. | $20M-$25M operating cash flow | report ↗ |
| 2022-Q3 | $0 | $12M | $29M+ $126M short-term inv. | $16M-$14M operating cash flow | report ↗ |
| 2022-Q2 | $0 | $14M | $16M+ $153M short-term inv. | $17M-$13M operating cash flow | report ↗ |
| 2022-Q1 | $0 | $13M | $12M+ $172M short-term inv. | $16M-$11M operating cash flow | report ↗ |
| 2021-Q3 | $0 | $11M | $11M+ $205M short-term inv. | $13M-$11M operating cash flow | report ↗ |
Annual history (5 years)
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2025-FY | $0 | $345M | $166M+ $540M short-term inv. | $90M-$279M operating cash flow | report ↗ |
For FY2025, Viking Therapeutics reported no revenue ($0M, flat YoY), R&D spend of $344.96M, up 239.4% YoY, and a net loss of $359.64M. Year-end cash and equivalents were $165.81M, and the company reported cash, cash equivalents and short-term investments of $706M.
Operationally, oral VK2735 is planned to advance into Phase 3 for obesity in 3Q26, while the Phase 3 VANQUISH trials for subcutaneous VK2735 remain ongoing, with VANQUISH-1 enrollment complete and VANQUISH-2 nearing full enrollment. A VK2735 maintenance dosing study is fully enrolled with data expected in 3Q26, and the company plans to file an IND for its novel amylin agonist this quarter. The company also highlighted VENTURE data presentations at ObesityWeek and a publication in the journal Obesity.
View 4 more years
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2024-FY | $0 | $102M | $27M+ $876M short-term inv. | $27M-$88M operating cash flow | report ↗ |
| 2023-FY | $0 | $64M | $56M+ $307M short-term inv. | $21M-$73M operating cash flow | report ↗ |
| 2022-FY | $0 | $54M | $37M+ $119M short-term inv. | $17M-$48M operating cash flow | report ↗ |
| 2021-FY | $0 | $45M | $26M+ $176M short-term inv. | $14M-$48M operating cash flow | report ↗ |
Insider transactions
Open-market activity, trailing 12 months: 1 purchase ($150K), 16 sales ($18.3M). Awards, option exercises and tax-withholding rows are listed below but excluded from these totals.
| Source | ||||||
|---|---|---|---|---|---|---|
| 2026-08-01 | Kelly-Gemmell Dorothy Elizabeth · director | Award / grant | 6,333 | — | — | Form 4 |
| 2026-08-01 | Kelly-Gemmell Dorothy Elizabeth · director | Award / grant (derivative) | 40,800 | — | — | Form 4 |
| 2026-07-29 | Mancini Marianna · Chief Operating Officer | Open-market sale | 18,217 | $33.47 | $610K | Form 4 |
| 2026-07-29 | ZANTE GREG · Chief Financial Officer | Open-market sale | 21,217 | $33.47 | $710K | Form 4 |
| 2026-07-29 | Lian Brian · director, President & CEO | Open-market sale | 148,517 | $33.32 | $4.9M | Form 4 |
| 2026-07-28 | Mancini Marianna · Chief Operating Officer | Award / grant | 31,667 | — | — | Form 4 |
| 2026-07-28 | ZANTE GREG · Chief Financial Officer | Award / grant | 31,667 | — | — | Form 4 |
| 2026-07-28 | Lian Brian · director, President & CEO | Award / grant | 221,667 | — | — | Form 4 |
Institutional holders
From SEC Form 13F filings for the quarter ended 2026-03-31 (filed up to 45 days later). 407 reporting institutions held 73.2M shares ($2.4B, 57.4% of shares outstanding).
| # | Institution | Shares | Value |
|---|---|---|---|
| 1 | BlackRock, Inc. | 6,880,290 | $223.9M |
| 2 | FMR LLC | 6,024,753 | $196.0M |
| 3 | VANGUARD CAPITAL MANAGEMENT LLC | 5,012,502 | $163.1M |
| 4 | VANGUARD PORTFOLIO MANAGEMENT LLC | 4,464,298 | $145.3M |
| 5 | TWO SIGMA INVESTMENTS, LP | 4,432,142 | $144.2M |
| 6 | STATE STREET CORP | 4,395,557 | $143.0M |
| 7 | RAYMOND JAMES FINANCIAL INC | 2,075,403 | $113.5M |
| 8 | MORGAN STANLEY | 3,013,928 | $98.1M |
| 9 | GEODE CAPITAL MANAGEMENT, LLC | 2,082,067 | $67.8M |
| 10 | AMERICAN CENTURY COMPANIES INC | 2,078,577 | $67.6M |
| 11 | AMERIPRISE FINANCIAL INC | 1,678,745 | $54.6M |
| 12 | D. E. Shaw & Co., Inc. | 1,676,713 | $54.6M |
| 13 | UBS Group AG | 1,347,472 | $43.8M |
| 14 | CITADEL ADVISORS LLC | 1,262,221 | $41.1M |
| 15 | GOLDMAN SACHS GROUP INC | 960,570 | $31.3M |